KMT2A and Ewing sarcoma: Thus, these studies highlight a potential therapeutic opportunity for Ewing sarcoma that could exploit ongoing TrxG-targeted strategies that are in preclinical and early clinical development for the treatment of MLL-driven leukemia [40].